You have accessJournal of UrologyReview Article1 Sep 2021Reply by Authorsis a reply to letterEditorial CommentEditorial Comment Eleanor Brain, Robert M. Geraghty, Catherine E. Lovegrove, Bingyuan Yang, and Bhaskar K. Somani Eleanor BrainEleanor Brain Newcastle Medical School, Newcastle-upon-Tyne, England More articles by this author , Robert M. GeraghtyRobert M. Geraghty *Correspondence: Department of Urology, Freeman Hospital, Freeman Road, Newcastle-upon-Tyne, UK telephone: 01913743848; E-mail Address: [email protected] http://orcid.org/0000-0002-9128-5173 Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, England Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Newcastle upon Tyne, England More articles by this author , Catherine E. LovegroveCatherine E. Lovegrove Department of Urology, Churchill Hospital, Oxford, England Nuffield Department of Surgery, Oxford University, Oxford, England More articles by this author , Bingyuan YangBingyuan Yang Department of Urology, Churchill Hospital, Oxford, England Financial and/or other relationship with Boston Scientific Corp. More articles by this author , and Bhaskar K. SomaniBhaskar K. Somani http://orcid.org/0000-0002-6248-6478 Department of Urology, University Hospital Southampton, Southampton, England More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001836.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail We thank Drs. Sur, Emmott and Chew for their considered editorials. We agree wholeheartedly that the term “clinically insignificant fragments” should be made defunct. As pointed out there was significant heterogeneity in followup imaging, definition of disease progression and definition of stone-free status. We recommend these be standardized for future studies so they may be directly comparable in future. This will aid patient counseling and informed consent. We can recommend, following the results of this study that: for imaging, postoperative computerized tomography should become the gold standard, disease progression should be defined as symptomatology or stone growth and that “stone-free” be defined as truly stone-free (ie no residual fragments). This study implies that not only will patient quality of life suffer if we accept “clinically insignificant fragments” as a treatment end-point, but also the costs associated with their disease if repeated interventions or time off work are needed (reference 4 in article). This is especially true of shock wave lithotripsy; given the high number of fragments generated, inevitably some will remain that will cause issues in the future, especially in those with chronic kidney disease.1 Further study needs to be made on how to differentiate patients into those to discharge, those to surveil or those to intervene. This is perhaps an area for implementation of a stone screen to identify high risk stone formers utilizing artificial intelligence and including patient and stone demographics, traditional risk factors, monogenic screen, polygenic risk score and 24-hour urinary biochemistry (reference 31 in article). Reference 1. : Role of endourological procedures (PCNL and URS) on renal function: a systematic review. Curr Urol Rep 2020; 21: 21. Google Scholar © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal of UrologyJun 16, 2021, 12:00:00 AMEditorial CommentJournal of UrologyJun 16, 2021, 12:00:00 AMEditorial Comment Volume 206Issue 3September 2021Page: 537-538 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Eleanor Brain Newcastle Medical School, Newcastle-upon-Tyne, England More articles by this author Robert M. Geraghty Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, England Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Newcastle upon Tyne, England *Correspondence: Department of Urology, Freeman Hospital, Freeman Road, Newcastle-upon-Tyne, UK telephone: 01913743848; E-mail Address: [email protected] More articles by this author Catherine E. Lovegrove Department of Urology, Churchill Hospital, Oxford, England Nuffield Department of Surgery, Oxford University, Oxford, England More articles by this author Bingyuan Yang Department of Urology, Churchill Hospital, Oxford, England Financial and/or other relationship with Boston Scientific Corp. More articles by this author Bhaskar K. Somani Department of Urology, University Hospital Southampton, Southampton, England More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...
Read full abstract